BALA CYNWYD, Pa. , May 21, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich’s ataxia (FA) and other complex rare diseases, today announced that it has executed a securities purchase

BALA CYNWYD, Pa. , May 20, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich’s ataxia (FA) and other complex rare diseases, today announced that the European Medicines Agency (EMA)

Data demonstrate proof-of-concept by showing that daily subcutaneous injections of CTI-1601 for up to 13 days resulted in dose-dependent increases in frataxin levels from baseline compared to placebo in all evaluated tissues Data show that frataxin levels achieved in peripheral tissues (buccal

- Topline data from placebo-controlled Phase 1 program in Friedreich's ataxia patients to be announced tomorrow, May 11, 2021 - Management to discuss during webcast and conference call at 8 a.m. ET - Cash and investments of $81.4 million as of March 31, 2021 BALA CYNWYD, Pa.

Reported preliminary Phase 1 findings from a Single Ascending Dose (SAD) trial that suggest single subcutaneous injections of CTI-1601 were well tolerated at doses up to 100 mg in Friedreich's   ataxia (FA) patients Placebo-controlled Phase 1 trials in FA patients remain on track for topline data

BALA CYNWYD, Pa. , Feb. 18, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon , MD, President and Chief Executive Officer of

BALA CYNWYD, Pa. , Dec. 15, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index

- Preliminary data   suggest that single subcutaneous injections of CTI-1601 were well tolerated at doses up to 100 mg - Company remains on track to report topline data from placebo - controlled single and multiple   ascending dose clinical trials in Q2 2021 BALA CYNWYD, Pa. , Dec.

BALA CYNWYD, Pa. , Nov. 13, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon , MD, President and Chief Executive Officer, will

Phase 1 trials evaluating CTI-1601 as a treatment for Friedreich’s ataxia   on track for topline data in 1H   2021 Received orphan drug d esignation for CTI-1601 from the European Commission Cash, cash equivalents, and marketable securities of $102 . 3 million as of September 30, 2020 BALA CYNWYD,